Clinical trials: Hepatitis B, completed
Chronic Hepatitis B
Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B
The aim of our study is to evaluate liver fibrosis using biochemical markers, FibroScan, and radiology methods in patients with chronic hepatitis B in mainland China.
- Trial name
- NCT01679769
- Where
- China
- Volunteers
- 818 people
- Sponsor
- Peking University First Hospital
Hepatitis B Vaccines
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults
- Trial name
- NCT03408730
- Testing
- Hepatitis B Vaccination
- Where
- 26 sites in United States, Belgium and 4 more
- Volunteers
- 2,838 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Bacterial Infections; Virus Diseases
A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of 4 different formulations of the HR5I vaccine (Haemophilus influenzae type b conjugate, recombinant hepatitis B surface antigen, diphtheria…
- Trial name
- NCT00551629
- Testing
- AR51 (12, 10), PR51 (3, 10), PR51 (6, 10)
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y
This study was conducted to evaluate the lot-to-lot consistency of three lots of HBV-MPL vaccine and to compare their safety and immunogenicity with that of Engerix™-B.
- Trial name
- NCT00696917
- Testing
- HBV-MPL vaccine 208129, Engerix™-B
- Where
- 7 sites in Australia, Czechia and 5 more
- Volunteers
- 1,303 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B
This is an open-label study evaluating multiple doses of NCO-48 Fumarate versus tenofovir alafenamide (TAF).
- Trial name
- NCT04629976
- Testing
- NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Nucorion Pharmaceuticals, Inc.
Infections, Meningococcal
Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study
This study will be conducted in three stages. In the DTP booster stage at 15 to 24 months of age, all subjects will receive a booster dose of Tritanrix™-HepB/Hiberix™.
- Trial name
- NCT00291343
- Testing
- Tritanrix™- HepB, Hiberix™, Mencevax™ ACWY
- Where
- 2 sites in Philippines
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg levels.
- Trial name
- NCT04129554
- Testing
- JNJ-73763989, JNJ-56136379, Entecavir (ETV) monohydrate
- Where
- 41 sites in Belgium, France and 5 more
- Volunteers
- 130 people
- Sponsor
- Janssen Sciences Ireland UC
Hepatitis B, Chronic
A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of combination regimens of JNJ-73763989+NA…
- Trial name
- REEF-1 (NCT03982186)
- Testing
- JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analog (NA)
- Where
- 108 sites in United States, Belgium and 17 more
- Volunteers
- 471 people
- Sponsor
- Janssen Sciences Ireland UC
Hepatitis B
Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine
This study will assess the immunogenicity, safety and reactogenicity of GSK Biological's DTPa-HBV-IPV/ Hib vaccine as compared to GSK's DTPa-IPV/Hib vaccine co-administered with HBV according to a three-dose immunisation course…
- Trial name
- NCT00880477
- Testing
- DTPa-HBV-IPV/Hib vaccine, DTPa-IPV/Hib vaccine, EngerixTM-B
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection
Background: Treatment of some diseases can suppress the immune system. This can cause other conditions to reactivate. Recent cases have shown that hepatitis B virus (HBV) reactivates in people who had already recovered from it…
- Trial name
- NCT03248622
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B Virus Infection
Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection
Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied.
- Trial name
- NCT06544551
- Testing
- Peginterferon Alfacon-2
- Where
- 34 sites in China
- Volunteers
- 336 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Kidney Disease
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
The purpose of the study is to demonstrate the safety and immunogenicity of a new investigational hepatitis B virus vaccine, HEPLISAV-B, in patients 18 to 75 years of age who have progressive loss of kidney function.
- Trial name
- NCT00985426
- Testing
- HEPLISAV-B, Engerix-B
- Where
- United States
- Volunteers
- 521 people
- Sponsor
- Dynavax Technologies Corporation
Hepatitis B
Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine
This study will assess immunogenicity, safety and reactogenicity of primary and booster vaccination.
- Trial name
- NCT00289796
- Testing
- DTPa-HBV-IPV/Hib
- Where
- Germany
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Inflammatory Bowel Diseases
Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab
Patients with Crohn's disease (CD) and ulcerative colitis (UC) are often treated with medications that suppress the immune system.
- Trial name
- NCT03056924
- Testing
- Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Boston Medical Center
Healthy
A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321
This is a single centre, three single administrations (Days 1, 29 and 57) at increasing doses of IMP321 (3, 10, 30 and 100 µg) in four cohorts of 12 subjects, single blind, randomized study.
- Trial name
- NCT00354861
- Testing
- hepatitis B antigen (without alum) plus IMP321, hepatitis B antigen alone (without alum), Engerix B
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Immutep S.A.S.
Hepatitis B, Hepatitis C
A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis
Cirrhosis is a diffuse lesion characterized by architectural distortion of the liver because of collagen deposition and development of nodules of regenerating hepatocytes.
- Conditions
- Hepatitis B, Hepatitis C, Liver Cirrhosis
- Trial name
- NCT00562783
- Testing
- Vitaliver
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hospital Authority, Hong Kong
Pediatric Immuno-Tolerant Chronic Hepatitis B
A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated…
- Trial name
- NCT02263079
- Testing
- Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
- Where
- 25 sites in United States, Australia and 10 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis
The purpose of this study is to determine if DNA vaccination of chronic HBV patients under treatment with NRTI can restore T-cell responsiveness and delay virologic reactivation after treatment discontinuation.
- Trial name
- VAC-ADN (NCT00536627)
- Testing
- DNA vaccine pCMVS2.S
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis B
Characterisation of Human B Cell Maturation in Response to Vaccination
This study is an exploratory single site sample collection study at St Mary's hospital campus, Imperial College London. Sixteen participants scheduled to receive routine immunizations for Td/IPV (group 1) and HBsAg (group 2) will…
- Trial name
- BVAC (NCT03535779)
- Testing
- Hepatitis B, Tetanus Toxoid
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hepatitis B
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)
This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.
- Trial name
- NCT01463683
- Testing
- 2XP HEPTAVAX™-II SC, 1XP HEPTAVAX™-II SC, 2XP HEPTAVAX™-II IM
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.